Follow us

About us

Founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix) and Pr Olivier Tillement (Professor of Chemistry at University of Lyon), NH TherAguix is a French biotechnology company based in Grenoble. NH TherAguix has developed an innovative theranostic nanodrug called AGuIX® that allows to fight more efficiently against all forms of cancer. 
Thanks to a €13M fund raising in 2019 (BPI, Innobio, Omnes, Arbevel, Supernova), NH THerAguix was able to launch a promising portfolio of clinical trials.

Partners

BPI France
Arbevel
Omnes
Supernova
Pulsayis
Université Claude Bernard Lyon 1
Région Auvergne Rhône-Alpes